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Transdermal systems for delivery of nitroglycerin have
been shown to provide sustained blood levels of the drug
for at least 24 hours. Investigations of hemodynamic
effectsof transdermal nitroglycerin in patients with heart
failure have demonstrated a transient reduction in pres-
sure lasting less than the expected 24 hours. These find-
ings could be due to the development of circulatory tol-
erance to the vasodilatory effects of nitroglycerin or to
insufficient drug dosing. In the present study, we com-
pared the hemodynamic effects of the first and the second
doses of high dose (120 mg) transdermal nitroglycerin
given 24 hours apart in 11 responders (2:20% reduction
in mean pulmonary artery wedge pressure lasting 2:2
hours).
Initiation of nitroglycerin therapy resulted in a sig-
nificant reduction in mean right atrial pressure lasting
for 14 hours and in a reduction in mean pulmonary
artery and mean pulmonary artery wedge pressures last-
ing 24 hours. After administration of the second dose,
mean right atrial pressure at 2 hours (9 ± 5 versus 7
± 4 mm Hg), 4 hours (8 ± 5 versus 6 ± 4 mm Hg)
and 8 hours (8 ± 5 versus 6 ± 3 mm Hg) was higher
than after the first dose (p < 0.05). Both mean pulmo-
Nitrates have been shown (1-3) to be effective therapeutic
mode for both the short- and long-term treatment of patients
with heart failure. The recent introduction of transdermal
systems of nitroglycerin administration has provided a rate-
controlled drug delivery device that can potentially maintain
a constant therapeutic drug concentration for at least 24
hours (4,5). Recent studies (6-8) limited to investigation
of the hemodynamic effect of first dose transdermal nitro-
glycerin in patients with heart failure have demonstrated a
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nary artery and mean pulmonary artery wedge pres-
sures were significantly higher after the second nitro-
glycerin dose. Mean pulmonary artery pressure after
the second dose was 32 ± 8 versus 28 ± 7 mm Hg at 2
hours (p < 0.05), 32 ± 7 versus 27 ± 7 mm Hg at 4
hours (p < 0.01), 33 ± 10 versus 27 ± 6 mm Hg at 6
hours (p < 0.05) and 31 ± 8 versus 26 ± 7 mm Hg at
8 hours (p < 0.05). Mean pulmonary artery wedge pres-
sure was 22 ± 7 versus 17 ± 7 mm Hg at 2 hours (p
< 0.01), 21 ± 8 versus 16 ± 6 mm Hg at 4 hours (p <
0.01), 19 ± 8 versus 16 ± 7 mm Hg at 6 hours (p <
0.05) and 20 ± 9 versus 15 ± 6 mm Hg at 8 hours (p
< 0.01).
It is concluded that in patients with chronic congestive
heart failure, the initial hemodynamic changes seen after
the administration of high dose transdermal nitroglyc-
erin are significantly attenuated within hours of the first
dose. These findings suggest that circulatory tolerance
to the effect of sustained nitroglycerin therapy develops
early and should be taken into consideration when trans-
dermal nitroglycerin is used in short- and long-term
therapy of chronic heart failure.
(1 Am Coil Cardiol 1987;9:858-64)
transient effect lasting less than the expected 24 hours, even
with high doses. These findings raised the possibility of
circulatory tolerance to the effects of sustained serum levels
of nitroglycerin, but could also be due to insufficient drug
dosing.
Our study was designed to further evaluate the persis-
tence of the circulatory response to sustained nitrate therapy
in patients with heart failure by using large dose transdermal
nitroglycerin and by comparing the effects of the first and
second doses of the drug.
Methods
Study patients. We studied 18 patients with chronic
severe congestive heart failure due to left ventricular systolic
dysfunction who were admitted to the hospital for worsening
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of symptoms, Eleven of these patients demonstrated a hemo-
dynamic response to transdermal nitroglycerin (>20% re-
duction in mean pulmonary artery wedge pressure seen within
4 hours after drug administration and lasting 2:2 hours) and
were included in our study, There were six women and f ve
men aged 21 to 77 years (mean ± SD 55 ± 18). The
diagnosis of left ventricular systolic dysfunction was based
on a reduced ejection fraction (measured in eight patients;
range 0.15 to 0.37, mean 0.24 ± 0.08) or echocardio-
graphic findings (three patients). Duration of heart failure
ranged between I and 8 years and the cause was believed
to be dilated cardiomyopathy in 10 patients and coronary
artery disease in I. Six patients with dilated cardiomyopathy
had a history of excessive chronic alcohol intake. No patient
had primary valvular disease or clinical evidence of active
myocardial ischemia at the time of the study. Three patients
had atrial fibrillationand eight had sinus rhythm. All patients
were in New York Heart Association functional class III or
IV and were in stable clinical and hemodynamic condition
at the time of study.
The study was started at least 24 hours after the insertion
of a balloon-flotation pulmonary artery catheter. All patients
were treated with digoxin, 0.25 mg daily, and all but one
(Patient I) received oral furosemide, 40 mg three times
daily; the dosage of these drugs was maintained constant
throughout the study. The administration of long-acting
vasodilator agents was discontinued at least 24 hours before
initiation of the study.
Hemodynamic measurements and computations. Right
heart catheterization was performed using a balloon-tipped,
triple-lumen, Swan-Ganz catheter, which allowed for mea-
surements of right atrial, pulmonary artery and pulmonary
artery wedge pressures. The reference point for the proce-
dure was at the midchest level with the patient in a supine
position. All pressures were recorded on an Electronics for
Medicine AR6 or VR12 recorder and mean pressures were
measured with the use of electronic integration, Heart rate
was determined by electrocardiographic recordings and sys-
temic blood pressures were determined by the standard cuff
method. Cardiac output was determined by thermodilution,
as previously described (9). Measurements were done in
triplicate using ice-cold 5% dextrose in water as the indi-
cator. Mean arterial blood pressure, cardiac index, stroke
volume index, stroke work index, systemic vascular resist-
ance and pulmonary vascular resistance were calculated us-
ing standard formulas (10).
Drug protocol. Baseline hemodynamic values were
measured at least 24 hours after the insertion of the pul-
monary artery catheter. Hemodynamic stability « 10%
variation) in heart rate, blood pressure, mean pulmonary
artery wedge pressure and cardiac output was ensured for
at least I hour by two or more hemodynamic measurements
before the initiation of therapy. Hemodynamic values de-
termined at the last measurement were used as baseline
values. A transdermal nitroglycerin system, 30 crrr' (Trans-
derm-Nitro, Ciba-Geigy), was used in this study; this system
is claimed by the manufacturer to release 15 mg of nitro-
glycerin over a 24 hour period (II). Because our previous
experience demonstrated a lack of significant hemodynamic
response to 30 to 60 (12) and 90 mg (8) in most patients
with severe heart failure, eight 30 mg patches were applied
to the chest wall of each patient in this study to provide the
release of 120 mg of nitroglycerin per 24 hours. Hemo-
dynamic measurements were repeated I, 2 and 4 hours after
the application of transdermal nitroglycerin. In II patients
who demonstrated hemodynamic response (2:20% reduction
in mean pulmonary artery wedge pressure lasting 2:2 hours),
measurements were repeated every 2 hours for 24 hours.
At that time. the nitroglycerin patches were removed and
replaced by the same number of fresh transdermal systems.
Hemodynamic measurements were repeated every 2 hours
for 8 hours after the application of the second dose. At that
point, the nitroglycerin patches were removed and hemo-
dynamic measurements were repeated in 10 of the patients
1 and 2 hours after discontinuation of therapy.
Statistical analysis. One way repeated measures anal-
ysis of variance (ANOVA) and the Newman-Keuls test (13)
were used to evaluate the temporal hemodynamic effects of
120 mg of transdermal nitroglycerin. Single comparisons
were performed with Student's t test for paired values. Anal-
yses were performed using the CLINFO system and the
SAS statistical package on the IBM 370 system at the Uni-
versity of Southern California. All values are expressed as
mean ± SD. A probability (p) value of <0.05 was con-
sidered statistically significant.
Results
Effect of first dose 120 mg transdermal nitroglycerin.
Heart rate, mean blood pressure, cardiac index and systemic
and pulmonary vascular resistance demonstrated no signif-
icant change throughout the 24 hours after the first nitro-
glycerin dose (Fig. I). A significant reduction was noted in
mean right atrial pressure after the application of nitroglyc-
erin (Fig. 2). This value fell from 10 ± 4 at baseline to 6
± 4 mm Hg at 4 hours (p < 0.05) and remained significantly
lower than the control value for 14 hours after nitroglycerin
administration. Mean pulmonary artery pressure was 38 ±
7 mm Hg at baseline and demonstrated a significant reduc-
tion to 31 ± 8 mm Hg at 1 hour, with maximal reduction
at 8 hours (26 ± 7 mm Hg). After 8 hours, mean pulmonary
pressure increased gradually but remained significantly lower
than the control value at 24 hours after initiation of therapy
(31 ± 6 mm Hg). Mean pulmonary artery wedge pressure
demonstrated a similar response to transdermal nitroglyc-
erin. The initiation of therapy resulted in a significant de-
crease from 26 ± 6 to 19 ± 5 mm Hg at I hour with peak
effect at 8 hours (15 ± 6 mm Hg). The reduction of this
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Figure 2. Sequential values in II patients of mean right atrial
pressure (RA), mean pulmonary artery (MPA) and mean pulmo-
nary artery wedge (PAW) pressures as measured at baseline (C)
and after the first (solid lines) and second (broken lines) doses
of 120 mg transdermal nitroglycerin. Shaded areas represent dif-
ference from control values.* p < 0.05.
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Figure l. Sequential effects in II patients of first dose 120 mg
transdermal nitroglycerin on heart rate. mean blood pressure, car-
diac index and systemic and pulmonary vascular resistances. All
changes in these variables were not statistically different from
baseline (C) values.
variable persisted for the entire 24 hours (19 ± 7 mm Hg,
p < 0.05).
Comparison between hemodynamic effect during the
first 8 hours after the administration of the first and the
second doses of transdermal nitroglycerin (Fig. 3 and
4). A comparison of the hemodynamic values at 2, 4, 6
and 8 hours after the administration of both nitroglycerin
doses demonstrated no significant difference in heart rate,
mean blood pressure, cardiac index and systemic and pul-
monary vascular resistances. Mean right atrial pressure was
significantly higher (p < 0.05) after the second than after
the first nitroglycerin dose at 2 hours (9 ± 5 versus 7 ±
4 mm Hg), 4 hours (8 ± 5 versus 6 ± 4 mm Hg) and 8
hours (8 ± 5 versus 6 ± 3 mm Hg). At 6 hours the
difference between the two values was not statistically sig-
nificant (9 ± 6 versus 6 ± 3 mm Hg). Both mean pulmonary
artery and mean pulmonary artery wedge pressures were
significantly higher after the second than after the first dose
of nitroglycerin. The respective values for mean pulmonary
artery pressure were 32 ± 8 versus 28 ± 7 mm Hg at 2
hours (p < 0.05), 32 ± 7 versus 27 ± 7 mm Hg at 4 hours
(p < 0.01),33 ± 10 versus 27 ± 6 mm Hg at 6 hours (p
< 0.05) and 31 ± 8 versus 26 ± 7 mm Hg at 8 hours (p
< 0.05). Mean pulmonary artery wedge pressures showed
similar differences: 22 ± 7 versus 17 ± 7 mm Hg at 2
hours (p < 0.01), 21 ± 8 versus 16 ± 6 mm Hg at 4 hours
(p < 0.01), 19 ± 8 versus 16 ± 7 mm Hg at 6 hours (p
< 0.05) and 20 :!:: 9 versus 15 :!:: 6 mm Hg at 8 hours (p
< 0.01).
Figure 3 demonstrates changes from control in right atrial,
pulmonary artery and pulmonary artery wedge pressures
after the administration of the two nitroglycerin doses given
24 hours apart. The reduction in mean right atrial pressure
at 2, 4 and 8 hours was significantly larger after the first
dose than after the second dose. The reduction in both mean
pulmonary artery and mean pulmonary artery wedge pres-
sures was significantly and progressively larger at each mea-
sured interval after the first nitroglycerin dose. The indi-
vidual values for mean pulmonary artery wedge pressure as
measured in all II patients after the first and second nitro-
glycerin doses are demonstrated in Figure 4. Complete at-
tenuation of initial effect was seen in three patients (Patients
3, 9 and II). Partial attenuation was seen in five patients
(Patients 4,5, 7,8 and 10). Patients 1,2 and 6 demonstrated
a persistent effect after the second dose.
Hemodynamic effect of abrupt discontinuation of ni-
troglycerin therapy. Figure 5 shows mean hemodynamic
values as measured at baseline, at 32 hours of continuous
nitroglycerin administration and then I and 2 hours after
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Figure 3. Comparison ofchanges from control inmean
right atrial (RA), mean pulmonary artery (PA) and
mean pulmonary artery wedge (PAW) pressures 2, 4,
6 and 8 hours after the administration of the first and
second doses of 120 mg transdermal nitroglycerin (NTG)
given 24 hours apart in II patients.
removal of the patches in to patients. Mean pulmonary
artery and wedge pressures at 32 hours of nitroglycerin
therapy were stilI significantly [ower than baseline values.
Abrupt discontinuation of nitroglycerin administration re-
suIted in return of these variables to baseline values. No
hemodynamic value recorded after discontinuation of ther-
apy was statistically different from baseline values, dem-
onstrating no demodynamic rebound.
investigators, (6,7) and by us (8) using [ower doses of the
drug. Our study extends previous findings and demonstrates
that the early diminution of hemodynamic effects of nitro-
glycerin cannot be fully restored with repeat administration
of the same dose of the drug and therefore is not likely to
Figure 4. Individual values in II patients of mean pulmonary
artery wedge pressure after the first and second doses of 120 rng
transdermal nitroglycerin.
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Discussion
Early attenuation of nitroglycerin effect. Attenuation
of early hemodynamic action has been a limiting factor in
the use of vasodilator drugs for short- and long-term treat-
ment of heart failure ( 14- [6). In contrast to other vasodilator
agents, the use of oral nitrates has been reported (2) to result
in a persistent hemodynamic effect without tolerance in
patients with chronic congestive heart failure. However, oral
administration of nitrates has certain limitations, including
a relatively short duration of action and sharp peaks and
valleys of blood levels, resulting in a need for frequent drug
dosing and a potential for great fluctuations in the degree
of effectiveness and safety during the dosage interval. The
recent attempt (I I) to use the transdermal route for admin-
istration of nitroglycerin has demonstrated the ability to
attain a relatively constant blood level of nitroglycerin for
at least 24 hours. Our results, however, demonstrate that a
significant attenuation of initial hemodynamic improvement
occurs within the first day of therapy with large dose trans-
dermal nitroglycerin. The reduction in pulmonary pressure
and right and left ventricular filling pressures that started
within 60 minutes of first dose nitroglycerin administration
demonstrated a gradual attenuation after reaching a peak at
4 to 8 hours of therapy. The administrationof a second dose
24 hours after initiation of therapy resulted in either no
response or a significantly attenuated response in most pa-
tients when compared with the effect of the initial nitro-
glycerin dose. A similar attenuation of transcutaneous ni-
troglycerin effect was recently demonstrated by other
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Figure 5. Group values in II patients for heart rate
(HR), mean blood pressure (MBP), mean right atrial
pressure (RA), mean pulmonary artery wedge pres-
sure (PAW), mean pulmonary artery pressure
(MPA) and systemic vascular resistance (SVR) at
baseline before initiation ofnitroglycerin therapy (C),
at32hours ofcontinuous nitroglycerin administration
(32 HR) and I hour (I HR P) and 2 hours (2 HR P)
after abrupt discontinuation of nitroglycerin. There
is no evidence of a hemodynamic rebound phenom-
enon.
be related to a decline in plasma level due to an insufficient
drug dose. This is supported by the work of Jordan et al.
(17), who recently documented persistence of the plasma
concentration of nitroglycerin for 24 hours after application
of 60 mg/24 h dosage of the drug in patients with heart
failure.
Our findings are based on the assumption that baseline
hemodynamics before the administration of the second ni-
troglycerin dose at 24 hours of therapy were comparable in
our patients with those measured before initiation of the
study. Because our study was designed to test the hypothesis
that steady state nitrate levels were associated with early
development of tolerance, a discontinuation of nitrate ther-
apy to reestablish baseline hemodynamics could potentially
prevent the development of tolerance, and was therefore not
performed. However, the relative stability of hemodynamics
in the same patient population using a similar protocol over
a periodof 24 hours has been previously demonstrated (7,18).
In a recent randomized crossover comparison of hemody-
namic effects of hydralazine and nifedipine in patients with
severe chronic heart failure, we (18) found comparable
hemodynamic data before the administration of both drugs
given approximately 24 hours apart. Jordan et al. (7), who
evaluated the hemodynamic response to transdermal nitro-
glycerin in comparison with placebo in a similar patient
population, found no statistically significant change in any
hemodynamic variable over 24 hours in patients treated with
placebo. In addition, hemodynamic measurements after dis-
continuation of continuous nitroglycerin therapy in our pa-
tients revealed values comparable with those obtained at
baseline before the initiation of therapy, indicating baseline
hemodynamic stability (Fig. 5).
Mechanisms of development of tolerance to nitro-
glycerin. The exact mechanism responsible for early re-
duction in efficacy of vasodilator drugs is not entirely clear;
however, cardiocirculatory tolerance to the vasoactivity of
these drugs seems to be a highly likely explanation. The
issue of tolerance development to circulatory effects of ni-
trates is not new and was first noted in animal studies (19,20).
Clinical studies (21,22) in patients with angina pectoris have
resulted in conflicting information; however, there is a large
body of recent data (22-27) supporting a development of
tolerance to hemodynamic as well as to anti-ischemic effects
of nitrates after continuous administration in patients with
angina pectoris. Although only limited information is avail-
able regarding long-term therapy in patients with heart fail-
ure, it seems that a long-term clinical effect is maintained.
Franciosa and Cohn (2) reported persistence of hemody-
namic effects of isosorbide dinitrate for 3 months without
the development of tolerance. Leier et al.(3) demonstrated
persistent improvement in exercise capacity and in pul-
monary capillary wedge pressure, pulmonary artery pressure
and pulmonary vascular resistance. These investigators,
however, found the development of tolerance to the effect
of the drug on both systemic vascular resistance and arterial
blood pressure. On the basis of these findings, a preferential
tolerance to the systemic arterial effect without attenuation
of the venous and pulmonary vascular effects of nitrates
was suggested when these drugs were used as therapy for
congestive heart failure.
Our study demonstrates that continuous transdermal ther-
apy with nitroglycerin is also associated with a rapid and
significant tolerance to the venous and pulmonary vascular
effects. The reason for the apparent difference in the re-
sponse of the venous and pulmonary circulations to nitrates
when given orally or transdermally is not entirely clear.
Recent data, however, suggest that nitrate tolerance is de-
pendent on dosage interval; it may be stimulated by sus-
tained high nitrate plasma concentration of the drug (26-29),
and could be delayed or prevented by nitrate-free intervals
lACC Vol. 9. No.4
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(23-30). These clinical findings have been in accordance
with experimental studies that demonstrated the develop-
ment of tolerance to the vasorelaxing effect of nitroglycerin
after continuous exposure to the drug. The tolerance to
nitroglycerin has been suggested (20) to be due to conversion
of sulfhydryl groups found in nitroglycerin receptors in vas-
cular smooth muscle to disulfides which demonstrate lower
affinity for nitrates.
Activation of vasoconstrictor mechanisms resulting from
stimulation of the sympathetic nervous system and renin-
angiotensin system has been suggested (15) to offset va-
sodilatory effects and thus to cause tolerance to vasodilator
therapy. This speculative mechanism of action has been
supported by a significant hemodynamic rebound reported
with discontinuation of vasodilators including nitrates (31,32).
Our experience with the use of high dose transdermal ni-
troglycerin in patients with heart failure in the present study
and in previous studies (8,12) has demonstrated an absence
of rebound hemodynamic response after removal of nitro-
glycerin systems in the majority of the patients. This finding,
in addition to a lack of change in plasma catecholamine
level or renin concentration during transdermal nitroglycerin
therapy (8,32), suggests that counterregulatory arterial va-
soconstriction is an unlikely mechanism for the observed
attenuation of nitroglycerin-mediated vasodilation in most
patients with chronic congestive heart failure.
Our data demonstrate continued attenuated effect on both
the pulmonary artery and left ventricular filling pressures
in spite of the tolerance to transdermal nitroglycerin. These
findings contradict previous findings by others (7) and by
us (8) demonstrating only short-lasting hemodynamic effects
with transdermal nitroglycerin in patients with heart failure.
This contradiction is probably due to the very large doses
used in our study and to the fact that only data in patients
who demonstrated an initial response ("responders") were
reported. Although there is attenuation of effect, the actual
level of the wedge pressure for the duration of our study
represents a positive response and could be beneficial to
patients responding to the drug. Further studies are neces-
sary to assess the long-term effect of high dose transdermal
nitroglycerin and the effect of nitrate-free intervals on the
restoration of nitroglycerin action in patients with chronic
heart failure.
Conclusion. This study demonstrates that in patients
with chronic severe heart failure who respond to high dose
transdermal nitroglycerin (120 mg), there is a rapid and
significant reduction in pulmonary pressures and in right
and left ventricular filling pressures after initiation of ther-
apy. However, a substantial attenuation of this response
occurs several hours after application of the first nitroglyc-
erin dose and cannot be reversed by administration of a
second dose. These findings suggest early development of
tolerance to the vasodilatory effect of transdermal nitro-
glycerin in most patients with severe chronic heart failure
and demonstrate a limitation of sustained, continuous ther-
apy with nitroglycerin for patients with chronic heart failure.
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